Physician profile
John L Bender
NPI 1609864065
$5,095.41
in general payments reported to CMS, 2019-2025
49 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $264 · 2021: $222 · 2022: $1,292 · 2023: $974 · 2024: $1,291 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.49 | 2021-2025 | Vraylar, Ubrelvy, Botox |
| Eko Health, INC. | $600.00 | 2022 | |
| Abbott Laboratories | $596.82 | 2022-2024 | Freestyle Libre 3, Infinity, Freestyle Libre 2 |
| Neurocrine Biosciences, INC. | $290.60 | 2020-2025 | Ingrezza |
| Pfizer INC. | $230.29 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.37 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $200.44 | 2022 | |
| Glaxosmithkline, LLC. | $196.52 | 2019-2024 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $148.22 | 2022-2024 | |
| Novo Nordisk INC | $120.30 | 2024 | Wegovy |
| Amgen INC. | $113.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $106.29 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $89.66 | 2019 | |
| Lilly USA, LLC | $87.36 | 2022-2023 | Mounjaro |
| Si-Bone, INC. | $81.12 | 2019 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.